Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Closer Look: Colorectal Cancer National Coverage Decision After One Year

Executive Summary

Nearly a year after CMS finalized a contentious national coverage decision (NCD) on certain off-label uses of colorectal cancer drugs, five out of nine eligible clinical trials have yet to open for patient enrollment, according to the National Cancer Institute (NCI)

You may also be interested in...



Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes

Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.

ESA Stakeholders May Find Clues About Medicare Revisions In Device NCDs

Pharma stakeholders could face an uphill battle convincing CMS to revise its recent final Medicare national coverage determination for the use of erythropoiesis-stimulating agents for non-renal indications, unless they can cite newly available published data, CMS' history of NCD reconsiderations suggests

ESA Stakeholders May Find Clues About Medicare Revisions In Device NCDs

Pharma stakeholders could face an uphill battle convincing CMS to revise its recent final Medicare national coverage determination for the use of erythropoiesis-stimulating agents for non-renal indications, unless they can cite newly available published data, CMS' history of NCD reconsiderations suggests

Related Content

Latest News
UsernamePublicRestriction

Register

PS046750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel